- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Contact Pharm Exec Editors
Subscription Support
Contact MMHInfo@mmhgroup.com for subscription-related questions only.
Press Releases and News Announcements
Send press releases and other announcements relevant to the pharma c-suite to pharmexec@mjhlifesciences.com.
Submit Article and/or Podcast Proposals
Use this form to submit article/podcast proposals.
Editorial Staff (US)
Mike Hollan
Assistant Managing Editor
mhollan@mjhlifesciences.com
Michael Christel
Group Managing Editor
mchristel@mjhlifesciences.com
Miranda Schmalfuhs
Group Social Media Editor
mschmalfuhs@mjhlifesciences.com
Don Tracy
Associate Editor
dtracey@mjhlifesciences.com
Custom Projects Staff
Colleen Hall
Vice President, Content and Special Projects
Jeanne Linke
Managing Editor
Megan Manzano
Senior Editor
Shannon Stolz
Senior Editor
Additional Information
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
Johnson & Johnson Seeks FDA Approval for Subcutaneous Tremfya Regimen for Ulcerative Colitis
November 22nd 2024Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA for a subcutaneous induction regimen of Tremfya for adults with moderately to severely active ulcerative colitis based on positive Phase III ASTRO trial results.
